What question did this study set out to answer?

This research aims to evaluate the effectiveness of low-dose tolvaptan in managing profound hyponatremia associated with SIAD.

January 10, 2026Kidney Medicine0 citationsOpen Access

Efficacy of Low-Dose Tolvaptan for Treatment of Profound Hyponatremia in Syndrome of Inappropriate Antidiuresis (SIAD): The EFFLUX-FLUID TRIAL

NJNarongchai JaiyenThammasat University SCSutatip ChinpraditsukThammasat University PPPattharawin PattharanitimaThammasat University

Key Points

This research aims to evaluate the effectiveness of low-dose tolvaptan in managing profound hyponatremia associated with SIAD.
Conducted a clinical trial

Structured PICO

Does low-dose tolvaptan improve [Na+] in patients with profound hyponatremia in SIAD who have predictors of fluid restriction failure?

Population

Patients with profound hyponatremia in Syndrome of Inappropriate Antidiuresis (SIAD) with predictors of fluid restriction failure

Intervention

Low-dose tolvaptan

Outcome

Increase in sodium concentration ([Na+])surrogate

Low-dose tolvaptan is an effective and safe strategy for rapidly correcting sodium levels in SIAD patients who are likely to fail standard fluid restriction.

Abstract

Low-dose tolvaptan effectively and rapidly increases Na+ in SIAD patients with predictors of fluid restriction failure, with acceptable safety under close monitoring.

Ask AI

Helpful

Bookmark

View Full Paper